The atherogenic bacterium Porphyromonas gingivalis evades circulating phagocytes by adhering to erythrocytes
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
The atherogenic bacterium Porphyromonas gingivalis evades circulating phagocytes by adhering to erythrocytes. / Belstrøm, Daniel; Holmstrup, Palle; Damgaard, Christian; Borch, Tanja S; Skjødt, Mikkel-Ole; Bendtzen, Klaus; Nielsen, Claus H.
I: Infection and Immunity, Bind 79, Nr. 4, 01.04.2011, s. 1559-65.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The atherogenic bacterium Porphyromonas gingivalis evades circulating phagocytes by adhering to erythrocytes
AU - Belstrøm, Daniel
AU - Holmstrup, Palle
AU - Damgaard, Christian
AU - Borch, Tanja S
AU - Skjødt, Mikkel-Ole
AU - Bendtzen, Klaus
AU - Nielsen, Claus H
PY - 2011/4/1
Y1 - 2011/4/1
N2 - A relationship between periodontitis and coronary heart disease has been investigated intensively. A pathogenic role for the oral bacterium Porphyromonas gingivalis has been suggested for both diseases. We examined whether complement activation by P. gingivalis strain ATCC 33277 allows the bacterium to adhere to human red blood cells (RBCs) and thereby evade attack by circulating phagocytes. On incubation with normal human serum, the P. gingivalis strain efficiently fixed complement component 3 (C3). Incubation of bacteria with washed whole blood cells suspended in autologous serum resulted in a dose- and time-dependent adherence to RBCs. The adherence required functionally intact complement receptor 1 (CR1; also called CD35) on the RBCs and significantly inhibited the uptake of P. gingivalis by neutrophils and B cells within 1 min of incubation (by 64% and 51%, respectively) and that by monocytes after between 15 min and 30 min of incubation (by 66% and 53%, respectively). The attachment of C3b/iC3b to bacterium-bearing RBCs decreased progressively after 15 min, indicating that conversion of C3 fragments into C3dg occurred, decreasing the affinity for CR1 on RBCs. We propose that P. gingivalis exploits RBCs as a transport vehicle, rendering it inaccessible to attack by phagocytes, and by doing so plays a role in the development of systemic diseases.
AB - A relationship between periodontitis and coronary heart disease has been investigated intensively. A pathogenic role for the oral bacterium Porphyromonas gingivalis has been suggested for both diseases. We examined whether complement activation by P. gingivalis strain ATCC 33277 allows the bacterium to adhere to human red blood cells (RBCs) and thereby evade attack by circulating phagocytes. On incubation with normal human serum, the P. gingivalis strain efficiently fixed complement component 3 (C3). Incubation of bacteria with washed whole blood cells suspended in autologous serum resulted in a dose- and time-dependent adherence to RBCs. The adherence required functionally intact complement receptor 1 (CR1; also called CD35) on the RBCs and significantly inhibited the uptake of P. gingivalis by neutrophils and B cells within 1 min of incubation (by 64% and 51%, respectively) and that by monocytes after between 15 min and 30 min of incubation (by 66% and 53%, respectively). The attachment of C3b/iC3b to bacterium-bearing RBCs decreased progressively after 15 min, indicating that conversion of C3 fragments into C3dg occurred, decreasing the affinity for CR1 on RBCs. We propose that P. gingivalis exploits RBCs as a transport vehicle, rendering it inaccessible to attack by phagocytes, and by doing so plays a role in the development of systemic diseases.
KW - Adolescent
KW - Adult
KW - Aged
KW - Atherosclerosis
KW - Bacterial Adhesion
KW - Cell Adhesion
KW - Cell Separation
KW - Complement Activation
KW - Complement C3
KW - Erythrocytes
KW - Female
KW - Flow Cytometry
KW - Humans
KW - Male
KW - Middle Aged
KW - Phagocytes
KW - Porphyromonas gingivalis
KW - Young Adult
U2 - 10.1128/IAI.01036-10
DO - 10.1128/IAI.01036-10
M3 - Journal article
C2 - 21245264
VL - 79
SP - 1559
EP - 1565
JO - Infection and Immunity
JF - Infection and Immunity
SN - 0019-9567
IS - 4
ER -
ID: 33878576